Meeting
2023 ASCO Annual Meeting
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).
Authors
Piyush Grover
Melanoma Institute Australia, The University of Sydney, Sydney, Australia
Piyush Grover , Isabel Li , Alexander M. Menzies , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2648)
DOI
10.1200/JCO.2023.41.16_suppl.2648
Abstract #
2648
Poster Bd #
490
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II trial of combination of PD-1 immune checkpoint inhibition with all-lesion stereotactic radiation (SBRT) in oligometastatic renal cell carcinoma (omRCC).
First Author: Jing Liu
Poster
2021 ASCO Annual Meeting
The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma.
First Author: Meghan Mooradian
Poster
2020 ASCO Virtual Scientific Program
Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.
First Author: Richard Lee O'Neal
Poster
2020 ASCO Virtual Scientific Program
Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors.
First Author: Steven Michael Blum